港股市场惊现"乌龙指"交易 东方电气盘中一度飙涨逾700% 东方电气在上午9时30分22秒出现一笔异常成交，以119.9港元/股的价格成交400股，较上一笔交易19.32 港元/股暴涨520%。该笔交易后，东方电气股价迅速回落至20.85港元/股附近。市场分析认为，这很可 能是交易员原本想以19.9港元买入，却误输入为119.9港元。受此影响，东方电气盘中一度飙涨 703.62%，创下历史最大单日波动。截至午间收盘，该股涨幅收窄至77.28%，报26.45港元/股。（上证 报） 年内已诞生3只主动权益"翻倍基" 全部来自创新药 今年以来，创新药板块逐步积累投资热度，主动权益基金中诞生出来的3只翻倍基，全部出自创新药板 块。其中，长城医药产业精选以119.66%的回报领跑今年以来的主动权益基金；永赢医药创新智选、中 银港股通医药净值亦同步狂飙，年内回报分别达106.37%、105.43%。（智通财经） 易方达基金张坤最新持仓曝光 郭良金任中国稀土董事长 天眼查App信息显示，7月18日，中国稀土发生工商变更，杨国安卸任法定代表人、董事长，由郭良金 接任，同时多位高管发生变更。中国稀土集团资源科技股份有限公司成立 ...

Group 1 - Haitong Development reported a net profit of 86.87 million yuan for the first half of 2025, a year-on-year decrease of 64.14% [1] - Haitong Development achieved an operating income of 1.8 billion yuan, a year-on-year increase of 6.74% [1] - Crystal Integrated expects a net profit increase of 39.04% to 108.55% for the first half of 2025, with projected revenue between 5.07 billion yuan and 5.32 billion yuan [1] Group 2 - Aerospace Universe anticipates a net profit increase of 50.59% for the first half of 2025, with a projected net profit of 34.38 million yuan [2] - Aerospace Universe's net profit excluding non-recurring gains is expected to grow by 94.90% [2] Group 3 - Guodian Power reported a total power generation of 206.03 billion kWh for the first half of 2025, a year-on-year decrease of 3.61% [3] - The company's market-based transaction electricity accounted for 91.84% of the total electricity sold [3] Group 4 - Shanghai Pharmaceuticals announced that its tranexamic acid injection has passed the consistency evaluation for generic drugs [5] - The drug is primarily used for treating various bleeding disorders [5] Group 5 - Sanyou Chemical received approval to issue up to 900 million yuan in technology innovation corporate bonds [7] - The bond issuance is valid for 24 months from the date of approval [7] Group 6 - Baiyuntian's BAT4406F injection drug has received approval for clinical trials for additional indications [9] - The drug is a next-generation fully human anti-CD20 antibody [9] Group 7 - Huason Pharmaceutical received three drug re-registration approval notices [10] - The approved drugs include Ganji Bingmei tablets and other formulations [10] Group 8 - Shanying International plans to establish the Zhiyuan Fund with a total scale of 100 million yuan [13] - The fund will primarily invest in product companies related to industrial scenarios [13] Group 9 - Yiqiu Resources announced the sale of two properties in Malaysia for a total of approximately 3.67 million yuan [15] - The sale is part of the company's asset management strategy [15] Group 10 - Guizhou Bailing plans to apply for loans totaling no more than 920 million yuan from multiple banks [16] - The loans will be used to replace maturing loans and supplement working capital [16] Group 11 - Samsung Medical's subsidiary won a transformer procurement contract in Brazil worth approximately 341 million yuan [16] - The contract is part of the company's expansion into international markets [16] Group 12 - Changying Tong expects a net profit increase of 72.12% to 110.33% for the first half of 2025 [17] - The projected revenue is between 173 million yuan and 211 million yuan [17] Group 13 - Canqin Technology anticipates a net profit increase of 50.14% to 61.85% for the first half of 2025 [17] - The expected revenue is between 286 million yuan and 290 million yuan [17] Group 14 - Daya Shengxiang signed a lease agreement with an annual rent of 17 million yuan for a production facility [18] - The lease term is for 3 years and 4 months, including a 4-month rent-free period [18] Group 15 - Zhongzai Zihuan announced the resignation of its general manager due to work adjustments [20] - The company will appoint an interim general manager while searching for a permanent replacement [20] Group 16 - Fuwei Co. received a project notification from a well-known luxury brand for seat development [22] - The total sales amount for the project is expected to reach 4.9 billion yuan [22] Group 17 - Meili Technology's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [26] - The issuance is subject to further approval from regulatory authorities [26] Group 18 - Jinzhik Technology announced a stock suspension due to potential control changes [27] - The suspension is expected to last no more than two trading days [27] Group 19 - Zhongtian Technology plans to distribute a cash dividend of 3 yuan per 10 shares [28] - The dividend distribution date is set for July 25, 2025 [28] Group 20 - Huahai Chengke plans to distribute a cash dividend of 0.2002 yuan per share [30] - The dividend distribution date is set for July 29, 2025 [30] Group 21 - Dasheng Intelligent won a smart transportation project contract worth 122 million yuan [31] - The project involves comprehensive monitoring systems for urban rail transit [31] Group 22 - Dongyue Silicon reported a fire incident affecting production operations [32] - The fire has been controlled, but the extent of damage is still being assessed [32] Group 23 - Shaanxi Guotou A reported a net profit of 726 million yuan for the first half of 2025, a year-on-year increase of 5.74% [35] - The company's operating income decreased by 2.95% [35] Group 24 - Yibo Technology announced a plan to reduce shareholding by up to 3% [37] - The reduction is due to the shareholder's funding needs [37] Group 25 - Xiling Information announced a stock suspension due to potential control changes [39] - The suspension is expected to last no more than two trading days [39] Group 26 - Tianli Lithium Energy plans to reduce shareholding by 4.55% through block trading [40] - The reduction is due to the fund's operational timeline nearing its end [40] Group 27 - Sihui Fushi announced plans for a combined shareholding reduction of up to 3% [42] - The reduction is due to the shareholders' personal funding needs [42] Group 28 - Jinma Leisure announced a plan for a combined shareholding reduction of up to 4.83% [44] - The reduction is due to personal funding needs of the controlling shareholder and executives [44] Group 29 - *ST Zitian's stock may be terminated due to financial reporting issues [46] - The company is under regulatory scrutiny for failing to rectify its financial statements [46]

证券代码：002424 证券简称：贵州百灵 公告编号：2025-036 贵州百灵企业集团制药股份有限公司 关于向银行申请贷款的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）于 2025 年7月18日召开的第六届董事会第十八次会议，审议通过了以下议案： | 序号 | 议案名称 | | --- | --- | | 1 | 《关于公司将于2025年12月31日前向中国工商银行股份有限公司 安顺分行申请续贷款不超过人民币52,000万元用于补充流动资金 | | | 的议案》 | | 2 | 《关于公司将于2025年12月31日前向中国农业银行股份有限公司 安顺分行申请续贷款不超过人民币5,000万元用于补充流动资金的 | | | 议案》 | | 3 | 《关于公司将于2025年12月31日前向浙商银行股份有限公司贵阳 | | | 分行申请续贷款不超过人民币10,000万元用于补充流动资金的议 | | | 案》 | | 4 | 《关于公司将于2025年12月31日前向中国光大银行股份有限公司 | | | 贵阳 ...

证券代码：002424 证券简称：贵州百灵 公告编号：2025-035 一、会议召开情况 1、贵州百灵企业集团制药股份有限公司（以下简称"公司"）第 六届董事会第十八次会议由公司董事长姜伟先生召集，会议通知于 2025年7月7日以专人送达、电子邮件、电话等通讯方式发出。 2、本次董事会于2025年7月18日上午10:00在公司三楼会议室以 现场结合通讯方式召开。 3、本次董事会应参会表决董事共9人，实际参会表决的董事9人。 其中独立董事胡坚、晏国菀、杨明、张洪武以通讯方式进行表决。 4、本次董事会由董事长姜伟先生主持，公司监事和高级管理人 员列席了本次董事会。 5、本次董事会的召集、召开符合《公司法》《公司章程》《董事 会议事规则》及相关法规的规定。 二、会议审议情况 贵州百灵企业集团制药股份有限公司 关于第六届董事会第十八次会议决议的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告 不存在虚假记载、误导性陈述或者重大遗漏。 经现场及通讯投票表决，会议审议通过了以下议案： 议案一、审议通过《关于公司将于2025年12月31日前向中国工商 银行股份有限公司安顺分行申请续贷款不超过人民币52,000 ...

Group 1: Marketing Reform and Sales Performance - The company initiated a direct sales reform pilot in 9 provinces starting in 2022, achieving significant results with steady profit growth in these regions [1] - The direct sales reform has been completed in 15 provinces, covering major OTC markets, which is expected to enhance sales efficiency and profitability [1] - The marketing reform introduced new performance metrics such as per capita efficiency and store efficiency, moving away from solely focusing on growth rates [1] Group 2: Financial Indicators and Profitability - The company is experiencing positive feedback from its marketing reform, with good completion rates for sales and payment indicators [2] - The company aims to exceed previous net profit levels, supported by steady growth of existing products and new drug development projects [2] - The company plans to enhance its profit margin to meet or exceed the industry average, ensuring long-term stable development [2] Group 3: New Drug Development - The Huanglian Jiedu Wan is the first "general" syndrome-type traditional Chinese medicine new drug in China, with clinical trials involving 840 cases [3] - The project employs a unique evaluation method combining "syndrome types + biomarkers," which could set a precedent for the evaluation standards of syndrome-type traditional Chinese medicine [3] - If approved, Huanglian Jiedu Wan will provide new treatment options for numerous diseases related to heat toxin syndrome [3] Group 4: Investment in Subsidiaries - Chengdu Zeling Biopharmaceutical Technology Co., Ltd. is a subsidiary in which the company holds a 17.6926% stake, making it the second-largest shareholder [3] - The subsidiary focuses on innovative drug research and has completed multiple rounds of financing [3]

Group 1 - Guizhou Province's Qiandongnan Prefecture has been severely affected by a major flood disaster, prompting immediate action from the Guizhou Securities Industry Association and its member units to provide aid and support [1] - As of July 4, 13 member units have participated in the relief efforts, donating a total of 943,700 yuan, which includes 231,500 yuan for emergency funding and 712,200 yuan worth of supplies to meet the urgent needs of affected residents [1] - Guizhou Southern Dairy Co., Ltd. mobilized aid supplies, sending four vehicles loaded with 14,100 cartons of milk to the disaster area to provide essential nutrition to the affected population [1] Group 2 - Guiyang Bank established a special task force and a "Youth Volunteer Service Team" to conduct post-disaster recovery efforts, ensuring the restoration of damaged facilities and providing basic living packages to affected employees [2] - Guizhou Langma Information Technology Co., Ltd. organized a team to deliver essential supplies to the disaster area, while Shanghai Zhonglian (Guiyang) Law Firm initiated a donation campaign to support the affected communities [3] - The Guizhou Provincial Transportation Planning and Surveying Design Institute formed an emergency response leadership group, with over 20 party members actively participating in on-site disaster relief efforts [3]

Group 1: Report General Information - The research object is Guizhou Bailing, belonging to the traditional Chinese medicine industry. The reception time was July 4, 2025, and the company's reception staff included the chairman, general manager, deputy general manager, financial director, and securities affairs representative [16] - The institutions participating in the research included Wang Lingyi, Pan Potao, Song Shijie, etc [2] Group 2: Company Business Analysis Marketing Reform - Since 2022, the company has launched a direct - sales system reform pilot in 9 provinces, and the reform has achieved remarkable results with steady growth in sales profits in reform areas. Currently, the direct - sales system reform has been completed in 15 provinces, which will positively impact the company's future sales efficiency and profitability [24] - The marketing model reform has changed the previous way of simply assessing growth rate, introducing assessment items such as per - capita efficiency and per - store efficiency, and reasonably formulating assessment indicators to mobilize the enthusiasm of sales staff. The company also plans to promote equity incentive plans in due course [24] - The company adheres to the profit - first orientation, optimizes the variety structure and price system, promotes the cultivation of large - scale varieties, and focuses on key national customers (NKA), regional large - scale chains (LKA), and the medical treatment sector to drive sales and profit growth [24] Sales Expense Optimization - The company's optimization of the sales expense ratio is a long - term task. It will continue to deepen the marketing system reform, gradually expand the coverage from the large - package model to the direct - sales model, and use the sales expense ratio in each region as a performance assessment indicator [24] - The company has established a market supervision department to vertically supervise the business activities and finances of branches and offices, and deeply participate in cost control and business negotiations [25] - Through optimizing and improving management, sales, and reward mechanisms, the company sets new assessment requirements for sales staff, strengthens budget assessment for direct - sales branches, and implements channel optimization policies for some varieties to reduce sales expenses. It also plans to promote equity incentive plans [25] Product R & D Progress - The Phase III clinical research of Tangning Tongluo is progressing normally according to the clinical protocol, and patients are being enrolled successively. The company will disclose information in a timely manner after achieving phased progress in R & D projects [26] Solvency - The company maintains long - term and stable cooperative relationships with multiple banks. After being removed from the risk warning list, the credit rating of the company by financial institutions will be upgraded. Considering factors such as the company's operating conditions, asset - liability structure, and asset utilization efficiency, the company does not have a solvency problem and will continue to optimize its asset - liability structure [26] Share Pledge - As of now, Chairman Jiang Wei holds 245,346,284 shares, accounting for 17.55% of the company's total shares, and 100% of his shares are pledged. The purpose of the share - pledged financing is for the investment and operation of non - listed company industries and the repayment of his stock - pledged repurchase transaction liabilities. The pledged shares do not bear performance compensation obligations [27] - Jiang Wei's total liabilities have been significantly reduced, and his credit status is good. The pledge risk is controllable, and there is currently no risk of forced liquidation. If such a risk occurs in the future, he will take measures such as early repurchase and additional pledges [27][28] R & D Expense Capitalization - The company manages R & D expenses in strict accordance with relevant accounting standards, and the annual report data has been audited by an accounting firm [29]

关于 2025 年第二次临时股东会决议的公告 特别提示： 1、本次股东会未出现否决提案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 证券代码：002424 证券简称：贵州百灵 公告编号：2025-034 贵州百灵企业集团制药股份有限公司 1、召开时间： 现场会议召开时间：2025年7月4日（星期五）上午十时 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为 2025 年 7 月 4 日（现场股东会召开当日）的交易时间，即 9:15—9:25,9:30—11:30 和 13:00—15:00。通过深圳证券交易所互 联网投票系统进行网络投票的开始时间为 2025 年 7 月 4 日（现场股 东会召开当日）9:15，结束时间为 2025 年 7 月 4 日（现场股东会结 束当日）15:00。 2、召开地点：贵州省安顺市经济技术开发区西航路 212 号贵州 百灵企业集团制药股份有限公司会议室 3、召开方式：现场投票和网络投票相结合的方式 4、会议召集人：公司董事会 5、会议主持人：董事长姜伟先生 6、本次股东会的召集和召开符合《公司法》《上市 ...

BEIDOUXING LAW OFFICE 贵州省贵阳市观山湖区金朱东路 399 号贵阳恒大中心 B 座 24 楼 邮编：550001 电话：86901517 传真：86901634 电子邮箱：1026333654@qq.com 关于贵州百灵企业集团制药股份有限公司 2025 年第二次临时股东会的 法 律 意 见 书 [2025] 黔北律法意见字第 234 号 致：贵州百灵企业集团制药股份有限公司 贵州北斗星律师事务所(以下简称"本所")接受贵州百灵企业集 团制药股份有限公司（以下简称"公司"）委托，指派本所律师郑锡 国、张妮出席了公司于 2025 年 7 月 4 日上午 10：00 在贵州省安顺市 经济技术开发区西航路 212 号贵州百灵企业集团制药股份有限公司 会议室召开的公司 2025 年第二次临时股东会（以下简称"本次股东 会"）。现根据《中华人民共和国公司法》、《中华人民共和国证券 法》等有关法律、法规及规章和《贵州百灵企业集团制药股份有限公 司章程》（以下简称（"公司章程"）、《贵州百灵企业集团制药股 份有限公司股东大会议事规则》（以下简称"议事规则"）的规定， 出具本法律意见书。 本所律师仅就本 ...

Core Viewpoint - Guizhou BaiLing is undergoing significant marketing reforms to enhance sales efficiency and profitability, with a focus on transitioning to a direct sales model across multiple provinces [2][3]. Group 1: Marketing Reform - The company initiated a direct sales reform pilot in nine provinces starting in 2022, which has led to steady profit growth in those regions [2]. - The reform has been implemented in a total of 15 provinces, aiming to improve sales efficiency and profitability [2]. - New performance metrics have been introduced, shifting from solely growth rate assessments to include per capita and per store efficiency, which motivates sales personnel [2]. Group 2: Sales Expense Management - The company is committed to optimizing its sales expense ratio through ongoing marketing system reforms and expanding coverage [2][3]. - A market supervision department has been established to oversee business activities and financial management across subsidiaries, enhancing cost control [3]. - The company is implementing new performance requirements for sales personnel and optimizing management and reward mechanisms to reduce sales expenses [3]. Group 3: Clinical Research Progress - The clinical research for Tangning Tongluo is progressing as planned, with patient enrollment ongoing [4]. Group 4: Financial Stability - The company maintains stable relationships with multiple banks, and its credit rating is expected to improve post-de-listing [5]. - The company does not face short-term solvency issues and is focused on optimizing its asset-liability structure [5]. Group 5: Shareholder Pledge - The chairman holds 17.55% of the company's shares, all of which are pledged for financing purposes unrelated to the company's operations [6]. - The chairman's debt has significantly decreased, and he has the capacity to repay, with no current risk of forced liquidation [6]. Group 6: R&D Expense Management - The company manages R&D expenses in accordance with accounting standards, with financial data audited by external firms [8]. - The company reported a significant decline in revenue and net profit in its Q1 2025 report, with total revenue of 761 million yuan, a 42.93% year-on-year decrease [8].